Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lu, Mei, Qingyun, Yu, Yongchao, Wang, Na, Zhang, Dou, Liao, Dongying, Zuo, Jinhui, Xie, Hongxia, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190697/
https://www.ncbi.nlm.nih.gov/pubmed/35707347
http://dx.doi.org/10.3389/fonc.2022.894214
_version_ 1784725848853577728
author Zhao, Lu
Mei, Qingyun
Yu, Yongchao
Wang, Na
Zhang, Dou
Liao, Dongying
Zuo, Jinhui
Xie, Hongxia
Jia, Yingjie
Kong, Fanming
author_facet Zhao, Lu
Mei, Qingyun
Yu, Yongchao
Wang, Na
Zhang, Dou
Liao, Dongying
Zuo, Jinhui
Xie, Hongxia
Jia, Yingjie
Kong, Fanming
author_sort Zhao, Lu
collection PubMed
description Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
format Online
Article
Text
id pubmed-9190697
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91906972022-06-14 Research Progress on RET Fusion in Non-Small-Cell Lung Cancer Zhao, Lu Mei, Qingyun Yu, Yongchao Wang, Na Zhang, Dou Liao, Dongying Zuo, Jinhui Xie, Hongxia Jia, Yingjie Kong, Fanming Front Oncol Oncology Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9190697/ /pubmed/35707347 http://dx.doi.org/10.3389/fonc.2022.894214 Text en Copyright © 2022 Zhao, Mei, Yu, Wang, Zhang, Liao, Zuo, Xie, Jia and Kong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhao, Lu
Mei, Qingyun
Yu, Yongchao
Wang, Na
Zhang, Dou
Liao, Dongying
Zuo, Jinhui
Xie, Hongxia
Jia, Yingjie
Kong, Fanming
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title_full Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title_fullStr Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title_full_unstemmed Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title_short Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
title_sort research progress on ret fusion in non-small-cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190697/
https://www.ncbi.nlm.nih.gov/pubmed/35707347
http://dx.doi.org/10.3389/fonc.2022.894214
work_keys_str_mv AT zhaolu researchprogressonretfusioninnonsmallcelllungcancer
AT meiqingyun researchprogressonretfusioninnonsmallcelllungcancer
AT yuyongchao researchprogressonretfusioninnonsmallcelllungcancer
AT wangna researchprogressonretfusioninnonsmallcelllungcancer
AT zhangdou researchprogressonretfusioninnonsmallcelllungcancer
AT liaodongying researchprogressonretfusioninnonsmallcelllungcancer
AT zuojinhui researchprogressonretfusioninnonsmallcelllungcancer
AT xiehongxia researchprogressonretfusioninnonsmallcelllungcancer
AT jiayingjie researchprogressonretfusioninnonsmallcelllungcancer
AT kongfanming researchprogressonretfusioninnonsmallcelllungcancer

Ejemplares similares